- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03629236
Study to Evaluate Safety and Efficacy of GrafixPL for the Treatment of Venous Leg Ulcers
April 11, 2022 updated by: Osiris Therapeutics
A Multicenter, Prospective, Randomized, Open-Label Study With a Crossover Extension Option to Evaluate the Safety and Efficacy of GrafixPL for the Treatment of Chronic Venous Leg Ulcers
A Multicenter, Prospective, Randomized, Open-Label Study with a Crossover Extension Option to Evaluate the Safety and Efficacy of GrafixPL for the Treatment of Chronic VLUs
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
200
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Florida
-
Doral, Florida, United States, 33126
- Integral Clinical Trial Solutions
-
-
Massachusetts
-
Weymouth, Massachusetts, United States, 02189
- SSH
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- 18 years or older, as of the date of screening
- An Index Ulcer that is chronic (defined as present for > 4 weeks, but not present for more than 52 weeks at Screening Visit 1)
- Index Ulcer is located on the leg, below the knee and above the malleoli (ulcer may be inclusive of the malleoli)
- The Index Ulcer is between 1 cm2 and 25 cm2, inclusive, at the Screening and Baseline Visits. The longest dimension of the index ulcer cannot exceed 10 cm at the Baseline Visit.
- The Index Ulcer has had compression therapy for > 2 weeks at Screening Visit 1
- The Index Ulcer extends into the dermis or subcutaneous tissue without evidence of exposed muscle, tendon, bone, or joint capsule
- Patient has adequate circulation to the foot, as documented up to 14 days prior to Screening Visit 1
- Confirmed diagnosis of venous insufficiency, as documented up to 30 days prior to enrollment
Exclusion Criteria:
- Index Ulcer is of non-venous pathophysiology
- Gangrene is present on any part of the affected limb
- Patient is unable to tolerate standard compression therapy
- Glycated hemoglobin A1c (HbA1c) level of > 14% in any patient with type 1 or type 2 diabetes mellitus, as documented up to 14 days prior to Screening Visit 1
- Patient is receiving intravenous (IV) corticosteroids, immunosuppressive or cytotoxic agents at any time during the screening period
- Patient has an ulcer within 5 cm of the Index Ulcer identified for study consideration
- Patient is Human Immunodeficiency Virus (HIV) positive or has Acquired Immune Deficiency Syndrome (AIDS)
- Current evidence of infection at the Index Ulcer, including cellulitis and/or pus drainage from the ulcer site at the time of Screening and Baseline Visits
- Evidence of osteomyelitis at the time of Screening and Baseline Visits
- Patient has active malignancy other than non-melanoma skin cancer
- Patient's Index Ulcer has decreased by ≥ 30% between Screening Visit 1 and the Baseline Visit during the screening period
- Patient has untreated alcohol or substance abuse at the time of Screening Visit 1
- Pregnant women and women who are breastfeeding
- Patient is currently enrolled in or has participated in another investigational device, drug, or biological trial within 30 days prior to Screening Visit 1
- Patient has had within 14 days of Screening Visit 1, or is currently undergoing, or is planning for ulcer treatments with growth factors, living skin, dermal substitutes or other advanced biological therapies
- Patient is an employee, or an immediate family member of an employee, of the sponsor company or site research staff conducting the study
- Patients who have already been randomized in Protocol 360 at any center may not be considered for screening or for re-entry into the trial at any center, even after the End of Treatment Study Visit
- Patients with a history of poor compliance, or an unwillingness or inability to adhere to the requirements of the protocol
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Control
|
Debridement, dressing application, standard compression therapy
|
Experimental: GrafixPL
|
Debridement, GrafixPL application, dressing application, standard compression therapy
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Complete closure of the index ulcer
Time Frame: Up to 84 days after the Baseline Visit
|
Up to 84 days after the Baseline Visit
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Time to initial ulcer closure
Time Frame: Up to 84 days after the Baseline Visit
|
Up to 84 days after the Baseline Visit
|
Measurement of percent area reduction in ulcers that do not achieve closure
Time Frame: 84 days after the Baseline Visit
|
84 days after the Baseline Visit
|
Proportion of patients with ulcer reoccurrence in Follow-Up Phase
Time Frame: Up to 6 months after initial ulcer closure
|
Up to 6 months after initial ulcer closure
|
Proportion of patients in the Crossover Extension Treatment Phase who achieve complete ulcer closure
Time Frame: Up to 91 days after initial Treatment Phase
|
Up to 91 days after initial Treatment Phase
|
Time to initial ulcer among patients in the Crossover Extension Treatment Phase
Time Frame: Up to 91 days after initial Treatment Phase
|
Up to 91 days after initial Treatment Phase
|
Other Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Number and type of AEs and SAEs
Time Frame: Through study completion, approximately 38 weeks
|
Through study completion, approximately 38 weeks
|
Number and type of ulcer related complications
Time Frame: Through study completion, approximately 38 weeks
|
Through study completion, approximately 38 weeks
|
CWIS Questionnaire
Time Frame: Through study completion, approximately 38 weeks
|
Through study completion, approximately 38 weeks
|
WPAI Questionnaire
Time Frame: Through study completion, approximately 38 weeks
|
Through study completion, approximately 38 weeks
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Study Chair: Jaideep Banerjee, PHD, Smith & Nephew, Inc.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
June 27, 2018
Primary Completion (Actual)
June 24, 2021
Study Completion (Actual)
June 24, 2021
Study Registration Dates
First Submitted
May 18, 2018
First Submitted That Met QC Criteria
August 10, 2018
First Posted (Actual)
August 14, 2018
Study Record Updates
Last Update Posted (Actual)
April 12, 2022
Last Update Submitted That Met QC Criteria
April 11, 2022
Last Verified
March 1, 2022
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- Osiris Protocol 360
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
product manufactured in and exported from the U.S.
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Venous Leg Ulcer
-
Gloucestershire Hospitals NHS Foundation TrustNot yet recruitingLeg Ulcer | Venous Leg Ulcer | Venous Insufficiency of Leg | Venous Ulcer
-
Tactile MedicalCompletedVenous Insufficiency | Venous Leg Ulcer | Chronic Venous Insufficiency | Venous Ulcer | Venous Stasis UlcerUnited States
-
DeRoyal Industries, Inc.Royal College of Surgeons, Ireland; Enterprise Ireland; Tyndall National InstituteCompletedVenous Leg Ulcer | Venous Insufficiency of LegIreland
-
Chang Gung Memorial HospitalRecruitingVenous Leg Ulcer | Venous Insufficiency of Leg | Venous Occlusion | Contrast Media ReactionTaiwan
-
Ortec InternationalCompletedVenous Leg Ulcer | Venous Stasis UlcerUnited States
-
W.L.Gore & AssociatesRecruitingVenous Leg Ulcer | Venous Stasis | Venous Stenosis | Venous Occlusion | Venous Ulcer | Venous Thromboses | Venous Disease | Vein Thrombosis | Vein Occlusion | Vein DiseaseUnited States
-
Firstkind LtdTerminatedLeg Ulcer | Venous Leg Ulcer | Venous UlcerCanada
-
W.L.Gore & AssociatesRecruitingVenous Leg Ulcer | Venous Stasis | Venous Stenosis | Venous Occlusion | Venous Ulcer | Venous Thromboses | Venous Disease | Vein Thrombosis | Vein Occlusion | Vein DiseaseUnited States, Australia, Germany, Italy, United Kingdom, New Zealand, Ireland
-
Firstkind LtdCompletedLeg Ulcer | Venous Leg Ulcer | Wound | Wound Leg | Leg Ulcers VenousUnited Kingdom
-
Mansoura UniversityActive, not recruitingVaricose Veins | Venous Insufficiency | Venous Leg Ulcer | Venous RefluxEgypt
Clinical Trials on GrafixPL
-
University of Texas Southwestern Medical CenterOsiris TherapeuticsCompleted